AUPR492201A0 - Novel mutation - Google Patents

Novel mutation

Info

Publication number
AUPR492201A0
AUPR492201A0 AUPR4922A AUPR492201A AUPR492201A0 AU PR492201 A0 AUPR492201 A0 AU PR492201A0 AU PR4922 A AUPR4922 A AU PR4922A AU PR492201 A AUPR492201 A AU PR492201A AU PR492201 A0 AUPR492201 A0 AU PR492201A0
Authority
AU
Australia
Prior art keywords
novel mutation
mutation
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR4922A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Priority to AUPR4922A priority Critical patent/AUPR492201A0/en
Publication of AUPR492201A0 publication Critical patent/AUPR492201A0/en
Priority to JP2002587594A priority patent/JP2004535178A/ja
Priority to PCT/AU2002/000581 priority patent/WO2002090532A1/en
Priority to EP02721852A priority patent/EP1385945A4/en
Priority to CA002446838A priority patent/CA2446838A1/en
Priority to US10/477,272 priority patent/US20040191791A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AUPR4922A 2001-05-10 2001-05-10 Novel mutation Abandoned AUPR492201A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AUPR4922A AUPR492201A0 (en) 2001-05-10 2001-05-10 Novel mutation
JP2002587594A JP2004535178A (ja) 2001-05-10 2002-05-09 新規変異
PCT/AU2002/000581 WO2002090532A1 (en) 2001-05-10 2002-05-09 Novel mutation
EP02721852A EP1385945A4 (en) 2001-05-10 2002-05-09 NEW MUTATION
CA002446838A CA2446838A1 (en) 2001-05-10 2002-05-09 Novel mutation
US10/477,272 US20040191791A1 (en) 2001-05-10 2002-05-09 Novel mutation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR4922A AUPR492201A0 (en) 2001-05-10 2001-05-10 Novel mutation

Publications (1)

Publication Number Publication Date
AUPR492201A0 true AUPR492201A0 (en) 2001-06-07

Family

ID=3828909

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPR4922A Abandoned AUPR492201A0 (en) 2001-05-10 2001-05-10 Novel mutation

Country Status (6)

Country Link
US (1) US20040191791A1 (enExample)
EP (1) EP1385945A4 (enExample)
JP (1) JP2004535178A (enExample)
AU (1) AUPR492201A0 (enExample)
CA (1) CA2446838A1 (enExample)
WO (1) WO2002090532A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530258A (en) 2001-07-18 2006-01-27 Bionomics Ltd Mutations in SCN1A SCN2A SCN3A SCN8A sodium ion channels and their use in diagnosing epilepsy
WO2008079412A2 (en) * 2006-12-22 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods and compositions to treat arrhythmias
EA201992358A1 (ru) 2017-04-03 2020-03-24 Инкоудид Терапьютикс, Инк. Тканеселективная экспрессия трансгена
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
WO2024038160A1 (en) * 2022-08-18 2024-02-22 Vib Vzw Means and methods to modulate neuron excitability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063367A1 (en) * 1999-04-15 2000-10-26 Warner-Lambert Company A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof
AU1846501A (en) * 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy

Also Published As

Publication number Publication date
EP1385945A4 (en) 2004-12-22
JP2004535178A (ja) 2004-11-25
US20040191791A1 (en) 2004-09-30
CA2446838A1 (en) 2002-11-14
EP1385945A1 (en) 2004-02-04
WO2002090532A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
AU2002365198A1 (en) Novel anti-infectives
AU2002359320A1 (en) Novel anit-infectives
AU2002360430A1 (en) 14-methyl-epothilones
AU2002330025A1 (en) Atlastin
AUPR573601A0 (en) Novel process
AU2002361985A1 (en) Microemulsifier
AU2002330790A1 (en) Ferro-sticker
AU2001100406A4 (en) DriverSMS
AUPR495301A0 (en) Novel mutation
AUPR799201A0 (en) Ferroportin-1 mutant
EP1225668A3 (de) Lasermodul
AU2002353664A1 (en) Routeplanner
AU2002366264A1 (en) Dioxathianones
AU2002953241A0 (en) Novel mutation
AU2002254979A1 (en) Novel sulfonylamino-pyrimidines
AU2002253663A1 (en) Novel maxizyme
AU2002355888A1 (en) Novel combination
AU2001100338A4 (en) Sunglove
AU2001100532A4 (en) FonePark
AU2001100214A4 (en) Dolly-trolley
AU2001100522A4 (en) e-Trans
AU2002238545A1 (en) Novel substituted imidazotriazinones
AU2002254880A1 (en) Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
AUPR480001A0 (en) Moulded panels
AU2002336207A1 (en) Novel process